Rein Therapeutics Price to Free Cash Flow Ratio 2017-2024 | RNTX

Rein Therapeutics price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as

Rein Therapeutics Price to Free Cash Flow Ratio 2017-2024 | RNTX

Rein Therapeutics price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$147B
Gilead Sciences (GILD)$116B
Bristol Myers Squibb (BMY)$115.8B
Vertex Pharmaceuticals (VRTX)$110.2B
CSL (CSLLY)$81.9B
Regeneron Pharmaceuticals (REGN)$74.7B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.6B
Alnylam Pharmaceuticals (ALNY)$34.4B
BioNTech SE (BNTX)$27.6B
Illumina (ILMN)$22.3B
BeiGene (ONC)$21.7B
Biogen (BIIB)$20.8B
Moderna (MRNA)$14.8B
Insmed (INSM)$14B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.9B
Genmab (GNMSF)$13.9B
Intra-Cellular Therapies (ITCI)$13.5B
Bio-Techne Corp (TECH)$12.5B
BioMarin Pharmaceutical (BMRN)$11.8B
Sarepta Therapeutics (SRPT)$11.1B
Vaxcyte (PCVX)$10.8B
QIAGEN (QGEN)$10.8B
Exact Sciences (EXAS)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Bio-Rad Laboratories (BIO.B)$9.8B
Exelixis (EXEL)$9.4B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B